Edge Therapeutics Inc. (Nasdaq: EDGE) reported disappointing interim results from a Phase 3 NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage. Shares of the biotechnology company crashed $14.28 to close at $1.31.
Disappointing study results for Edge Therapeutics
March 28, 2018 at 18:14 PM EDT
